Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artemis Therapeutics, Inc.ATMS · Entity 124649 | Chief Executive Officer | March 15, 2018 | March 19, 2018 |
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director · President and CEO | March 12, 2026 | March 12, 2026 |
| Savara IncMSTX · Entity 4900 | Director · CEO and Director | January 20, 2017 | January 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artemis Therapeutics, Inc.
Report date March 15, 2018 · Filed March 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2028-03-15 | Direct | 48,528 |
Reported balance
After 2018-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-15 · Grant · Acquired 48,528 · Balance 48,528 |
Lineage Cell Therapeutics, Inc.
Report date March 12, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 255,516 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Purchase · Acquired 15,000 · Balance 255,516 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.
Savara Inc
Report date January 20, 2017 · Filed January 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,368,194 |
Reported balance
After 2017-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-20 · Grant · Acquired 2,368,194 · Balance 2,368,194 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Dec 31, 2020 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $1.76 | $27,192.00 |
DisclosureSEC source: 0001493152-20-024692 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 30, 2020 Filed Sep 30, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-018634 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,150 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| September 30, 2020 Filed Sep 30, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $0.94 | $5,004.25 |
DisclosureSEC source: 0001493152-20-018634 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,495 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 30, 2020 Filed Sep 30, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $0.94 | $14,470.47 |
DisclosureSEC source: 0001493152-20-018634 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012542 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,600 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $0.87 | $4,648.41 |
DisclosureSEC source: 0001493152-20-012542 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,388 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $0.87 | $13,441.50 |
DisclosureSEC source: 0001493152-20-012542 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-005529 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,050 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $0.83 | $4,424.54 |
DisclosureSEC source: 0001493152-20-005529 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,281 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $0.83 | $12,794.15 |
DisclosureSEC source: 0001493152-20-005529 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,233,300 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-20-004349 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,300 Underlying: Common Shares · 1,233,300 shares Expires 2030-03-17 F1 · derivative.exercise_date: One quarter of the options shall vest on March 17, 2021 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-019942 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,500 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $0.89 | $4,755.27 |
DisclosureSEC source: 0001493152-19-019942 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,174 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-019942 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014834 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,950 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $0.98 | $5,236.14 |
DisclosureSEC source: 0001493152-19-014834 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,067 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014834 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 61,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014321 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,400 Underlying: Common Shares · 61,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 200,000 RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. See note 1 for certain information regarding an adjustment to the number of shares subject to these RSUs. F4 · derivative.expiration_date: The Reporting Person was granted 200,000 RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. See note 1 for certain information regarding an adjustment to the number of shares subject to these RSUs. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 21,371 | $1.00 | $21,371.00 |
DisclosureSEC source: 0001493152-19-014321 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,960 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 61,800 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 61,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014321 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. In connection with the issuer's distribution of shares of common stock of AgeX, Inc. it owned to all its shareholders, the number of shares subject to these RSUs was adjusted from 200,000 to 247,200 to maintain the intrinsic value of the award. See the issuer's proxy statement as filed with the Securities and Exchange Commission on June 14, 2019 for additional information regarding such distribution. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 12:39 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 10,000 | $1.01 | $10,100.00 |
DisclosureSEC source: 0001209191-19-046029 · doc4.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,531 F1 · balance_after: The number of common shares beneficially owned by the reporting person includes 15,411 additional common shares that were issued to the reporting person to maintain the intrinsic value of restricted stock unit awards immediately prior to the issuer's distribution of common stock of AgeX, Inc. See the issuer's proxy statement as filed with the Securities and Exchange Commission on June 14, 2019 for additional information. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001577 · doc4.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vested on January 1, 2019. F4 · derivative.expiration_date: The restricted stock units vested on January 1, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 40,880 | $0.91 | $37,323.44 |
DisclosureSEC source: 0001209191-19-001577 · doc4.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,120 F3 · shares: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 100,000 Restricted Stock Units, the grant of which was previously reported on a Form 8-K. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001577 · doc4.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| September 17, 2018 Filed Sep 20, 2018 01:07 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051722 · doc4.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one Common Share. F5 · derivative.exercise_date: Subject to continuous service, the restricted stock units shall vest fully on January 1, 2019. F5 · derivative.expiration_date: Subject to continuous service, the restricted stock units shall vest fully on January 1, 2019. Read SEC document |
| September 17, 2018 Filed Sep 20, 2018 01:07 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051722 · doc4.xml · derivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires not disclosed F3 · derivative.exercise_price: Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one Common Share. F4 · derivative.exercise_date: Subject to continuous service, one quarter of the restricted stock units shall vest on September 17, 2019 and the balance shall vest in twelve equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: Subject to continuous service, one quarter of the restricted stock units shall vest on September 17, 2019 and the balance shall vest in twelve equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| September 17, 2018 Filed Sep 20, 2018 01:07 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantNon-Qualified Option to Purchase Common Shares · Derivative | 1,500,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-18-051722 · doc4.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Shares · 1,500,000 shares Expires 2028-09-16 F1 · security: Inducement option grant made outside the BioTime 2012 Equity incentive Plan, as amended, in reliance on the employment inducement exemption to shareholder approval provided under the New York Stock Exchange's Listed Company Manual Rule 303A.08. F2 · derivative.exercise_date: Subject to continuous service, one quarter of the options shall vest on September 17, 2019, and the balance of the options shall vest in 36 equal monthly installments at the end of each one-month period thereafter. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:17 UTC | Artemis Therapeutics, Inc. ATMS · Entity 124649 | GrantStock Option (Right to Buy) · Derivative | 48,528 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001178913-18-000896 · zka1821374.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,528 Underlying: Common Stock · 48,528 shares Expires 2028-03-15 Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 12:12 UTC | Artemis Therapeutics, Inc. ATMS · Entity 124649 | PurchaseWarrant · Derivative | 12,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001178913-17-002876 · zk1720650.xml · derivative · entry 2 Culley Brian M · CIK 0001310683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2022-10-23 F1 · price: The reported securities consist of units purchased by the reporting person for $1.00 per unit. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 12:12 UTC | Artemis Therapeutics, Inc. ATMS · Entity 124649 | PurchaseCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-17-002876 · zk1720650.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The reported securities consist of units purchased by the reporting person for $1.00 per unit. Read SEC document |
| August 09, 2017 Filed Sep 5, 2017 20:37 UTC | Artemis Therapeutics, Inc. ATMS · Entity 124649 | GrantStock Option (Right to Buy) · Derivative | 242,640 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001178913-17-002618 · zk1720526.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,640 Underlying: Common Stock · 242,640 shares Expires 2027-08-09 F1 · derivative.exercise_date: The option, representing a right to purchase 242,640 shares of the Issuer's common stock at an exercise price of $1.30 per share, vests ratably over a 48 month period commencing on the first day of the month following the date of issuance. Read SEC document |
| January 20, 2017 Filed Jan 23, 2017 22:18 UTC | Savara Inc MSTX · Entity 4900 | GrantRestricted Stock Units · Derivative | 2,368,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005130 · doc4.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,368,194 Underlying: Common Stock · 2,368,194 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). F2 · derivative.expiration_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.